Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)Pei‐Pei Kung, Martin P. Edwards, Rita Grantner et al.|Journal of Medicinal Chemistry|2017Cited by 128
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2 <i>H</i> )-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) InhibitorsPei‐Pei Kung, Martin P. Edwards, Eugene Rui et al.|Journal of Medicinal Chemistry|2016Cited by 69
Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growthAnthony M. Barsotti, Robert A. Rollins|Oncotarget|2015Cited by 45
CCDC 1982336: Experimental Crystal Structure DeterminationPei‐Pei Kung, Martin P. Edwards, Patrick Bingham et al.|The Cambridge Structural Database|2020Cited by 0